IMM-101 and Cancer
Immodulon is dedicated to the development of novel, safe and effective combination treatments for cancer patients. Patients with diagnoses including Pancreatic, Melanoma, Mesothelioma, Lung, Glioblastoma and Colorectal cancers, have been treated with our lead product, IMM-101, either in clinical studies or compassionate use programmes.
Immodulon sponsored clinical studies with repeated intradermal injections of IMM-101 to date have shown that IMM-101 is well tolerated and may potentially increase the overall survival of patients with metastatic Pancreatic cancer and advanced Melanoma with no incremental burden of side effects.
Immodulon’s vision is for IMM-101 to become a backbone immunotherapy across multiple cancer types in combination with any of the four major pillars of cancer therapy – immunotherapy (including innovative checkpoint inhibitors (CPIs), chemotherapy, radio/ablation therapy, and surgery – and increase their efficacy without compromising on patient’s safety and quality of life. Our present and future clinical trials, including studies sponsored by our collaborators, are designed with this vision in mind.
Our key focus is on developing better therapies for the different areas in advanced Pancreatic cancer and to advance Immodulon’s pipeline in cancer indications where there has been hardly any progress in survival over the last decades.
Pancreatic cancer (pancreatic ductal adenocarcinoma)
With few effective therapies for Pancreatic cancer, it remains one of the most challenging cancers to treat with majority of Pancreatic cancers becoming metastatic. It has a 5-year survival rate of only 5-10%, accounts for 7% of all the cancer deaths and is expected to become the second leading cause of death from cancer in the US by 2030. Pancreatic cancer is observed in four different stages:
- local and surgically resectable (10-20% incidence and a 5-year survival of about 20%)
- local and borderline surgically resectable (5-15% and <5%)
- locally advanced and surgically unresectable (20-30% and <3%)
- metastatic (45-55% and <1%)
Immodulon successfully completed a Phase II randomized study (IMM-101-0021) comparing IMM-101 with and without gemcitabine in 110 patients. 18 patients had locally advanced Pancreatic cancer and 92 had metastatic disease. IMM-101 demonstrated a favourable safety profile for all patients with an increased overall survival in metastatic disease.
Immodulon’s long-term follow-up study (IMM-101-002A2), included 11 patients with metastatic disease at entry to the first study. The survival probability at 24, 30 and 36 months indicated long-term benefits for IMM-101 used in combination with other anti-cancer treatments and showed survival probabilities beyond 24 months comparable to the more toxic, standard of care combination of Abraxane plus gemcitabine in a small number of patients.
The Company plans to commence recruitment in H2-2022 for its Phase III randomised global study in metastatic Pancreatic cancer patients who are not suitable candidates for FOLFIRINOX treatment. This study will recruit patients with untreated metastatic Pancreatic cancer who are ECOG Performance Status 0,1 or 2 and are 65 years of age or older, or patients that are younger and are not suitable for FOLFIRINOX treatment in the opinion of their doctor. The study will evaluate the effect of IMM-101 in combination with gemcitabine and nab-paclitaxel.
Additionally, following the positive Phase II study, IMM-101 is under evaluation in patients with different stages or forms of Pancreatic cancer treatments in combination with immune-based therapies (CPIs and others), chemotherapy, local radiation, ablation therapies, surgery, and potentially combinations of these treatments. These investigator sponsored studies will be conducted in major European centres of excellence.
An investigator sponsored open label, non-randomised study (“LAPC-2”) of IMM-101 in Locally Advanced Pancreatic Cancer (LAPC) is being conducted at the Erasmus University Medical Centre in Rotterdam. The LAPC-2 study is designed to evaluate the safety and efficacy of IMM-101 administered in combination with stereotactic radiotherapy of the primary tumour in LAPC patients who initially responded to FOLFIRINOX. The study completed recruitment in Q3 2021 and results will be reported in due course.
Based on the initial observations in LAPC-2, a second open label, non-randomised investigator sponsored study commenced in Q1-2021 in patients with limited metastatic Pancreatic cancer (“MEPANC-1”). The trial is designed to evaluate the safety and efficacy of IMM-101 administered in combination with stereotactic radiotherapy on metastases in the liver and lung. Recruitment is ongoing.
Preparation is underway for additional investigator sponsored studies with IMM-101 in advanced Pancreatic cancers include combinations with CPIs in metastatic (in collaboration with a pharma partner), locally advanced disease and combinations with CPIs and other immunotherapies in metastatic disease.
Immodulon has completed two clinical trials of IMM-101 in Melanoma. A Phase I study in 18 patients with advanced unresectable Melanoma to investigate safety and tolerability (IMM-101-0013) and an open label follow up study (IMM-101-008) with 10 of these patients, who were observed for nearly eight years. In these studies, IMM-101 demonstrated a favourable safety profile with encouraging long-term survival data4.
Immodulon recently completed a Phase II study (“IMM-101-015“) in advanced unresectable Melanoma demonstrating a favourable safety and efficacy profile of IMM-101 in combination with the CPI Nivolumab. Full analysis of the study will be presented at ASCO on 3-7 June 2022.
Colorectal cancer – also known as bowel cancer, colon cancer, or rectal cancer – is the second leading cause of cancer death in women, and the third for men. The cancer can grow through the gut wall (stage III) and spread to other parts of the body (Stage IV).
Immodulon completed an exploratory Phase I/II study of IMM-101 in patients with advanced Colorectal cancer which demonstrated a favourable safety profile. Immodulon has partnered with Roche Pharma AG and Essen in an investigator sponsored Phase II open-label, prospective, multicentre study of CPI, Atezolizumab, with or without IMM-101 in 120 patients with Colorectal cancer. Recruitment is ongoing (“ANTONIO“).